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Objective: We reviewed our experience with iatrogenic chylothorax after pulmonary
resections for lung cancer to evaluate our treatment strategy and to identify factors
that predict the need for reoperation.
Methods: From July 1992 through February 2000, a total of 1110 patients under-
went pulmonary resection (at least lobectomy) and systematic mediastinal lymph
node dissection for lung cancer at our division. Twenty-seven patients (2.4%) had
postoperative chylothorax develop. We initially treated 26 of these patients conser-
vatively with complete oral intake cessation and total parenteral nutrition, and these
patients constituted the subjects in this study.
Results: There were 21 men and 5 women with a median age of 62 years (range 44
to 80 years). The initial procedures were pneumonectomy in 2 cases, bilobectomy
in 1 case, and lobectomy in 23 cases. Twenty-one patients (81%) had the condition
cured with conservative treatment. These patients resumed a normal diet at a median
of 8 days after chylothorax diagnosis (range 4-35 days). The remaining 5 patients
(19%) underwent reoperation at a median of 14 days after diagnosis (range 5-35
days). Chest tube drainage of less than 500 mL during the first 24 hours after
complete oral intake cessation and total parenteral nutrition predicted a cure with
conservative treatment.
Conclusion: Although most cases of chylothorax after pulmonary resection with
systematic mediastinal lymph node dissection can be cured with a conservative
strategy, early surgical intervention may be indicated if chest tube drainage is more
than 500 mL during the first 24 hours after complete oral intake cessation and total
parenteral nutrition.
Postoperative chylothorax is a rare but well-known complication inthoracic surgery.1 The thoracic duct lies posterior to the aorta andcourses to the right of the spine. It usually crosses to the left ventralto the fifth thoracic vertebra, ascends into the neck posterior to theaortic arch, and empties into the left jugulosubclavian junction. Itsproximity to the trachea, the presence of collateral channels, and its
highly variable anatomic course can lead to an injury to this lymphatic flow during
pulmonary resection, especially during mediastinal lymph node dissection. We
reviewed our experience with iatrogenic chylothorax after pulmonary resection with
systematic mediastinal lymph node dissection for lung cancer, as previously de-
scribed by Naruke,2 to evaluate our treatment strategy and to identify factors that
predict the need for reoperation.
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Patients and Methods
From July 1992 through February 2000, a total of 1110 patients
underwent pulmonary resection (at least lobectomy) and system-
atic mediastinal lymph node dissection for lung cancer at our
division, as described previously elsewhere.2 Postoperative chylo-
thorax developed in 27 patients (2.4%), and these patients consti-
tuted the subjects in this study. Chylothorax was diagnosed on the
basis of chylous leakage from the chest tube. The diagnosis was
confirmed by presence of triglycerides (110 mg/dL) and chylo-
microns in the drainage fluid.3 The medical records of these
patients were reviewed for age, sex, surgical procedures, patho-
logic findings, amount of chest tube dainage, and chylothorax
treatment methods. Lung cancer was pathologically staged accord-
ing to the the TMN classification system of the American Joint
Committee on Cancer Staging.4
We initially treated all but one of these patients conservatively
with complete oral intake cessation and total parenteral nutrition
(TPN); the exception was treated with a medium-chain triglyceride
diet and was therefore excluded from the study. If chest tube
drainage did not decrease significantly in about 3 days, we per-
formed pleurodesis by injecting a preparation of 10 kE OK-432
plus 20 mL 1% lidocaine plus 20 mL isotonic sodium chloride
solution (Picibanil; Chugai Pharmaceutical Co Ltd, Tokyo, Japan)
into the thoracic cavity through a chest tube.5 If chylothorax was
not cured in about 2 weeks, the conservative strategy was consid-
ered unsuccessful and surgical intervention was indicated.
Results
There were 21 male and 5 female patients. Their ages
ranged from 44 to 80 years, with a median age of 62 years.
Patient characteristics are shown in Table 1. Pneumonec-
tomy was performed in 2 cases, with the chest tube kept in
place until the third postoperative day for unrecorded rea-
sons in 1 case. Bilobectomy was performed in 1 case, and
lobectomy was performed in 23 cases. All patients had a
single chest tube placed after the initial operation. All chy-
lothoraces developed on the ipsilateral side. Chylothorax
was diagnosed at a median of 2 days after operation (range
1-3 days; Table 2). All patients were treated with complete
oral intake cessation and TPN. Fifteen patients (58%) re-
ceived pleurodesis with OK-432 (Table 2), and 13 (87%) of
them had the condition cured with the conservative treat-
ment. There were no procedure-related complications, drug-
related complications, or deaths related to the thoracic cav-
ity injection of OK-432. The only adverse effects, fever and
chest pain, were mild and controllable by medication. In
total, 21 patiens (81%) had the chylothorax cured with this
conservative strategy. These patients resumed a normal diet
at a median of 8 days after chylothorax diagnosis (range
4-35 days). One patient resumed a normal diet at 35 days
after chylothorax diagnosis, wheras all the others did so
between 4 and 15 days after chylodthorax diagnosis.
The remaining 5 patients (19%) underwent reoperation.
The median chest drainage volume during the first 24 hours
after complete oral intake cessation and TPN in this group
was 706 mL, as opposed to 215 mL for the patients who had
the condition cured by the conservative strategy. The chest
drainage volume during the first 24 hours after complete
oral intake cessation and TPN for the conservative cure
group did not exceed 500 mL (Figure 1). Reoperation was
performed at a median of 14 days after pulmonary resection
(range 5-35 days). Reoperation was successful in all cases.
There were no deaths among the 26 patients. Complica-
tions occurred in 4 cases (15%): atrial fibrillation in 1
patient, pneumonia in 2 patients, and a mediastinal chyloma
after seemingly successful conservative treatment in 1 pa-
tient.6
Discussion
Postoperative chylothorax is an uncommon but well-known
complication in thoracic surgery. In our review, we encoun-
tered 27 patients (2.4%) with chylothorax among 1110 who
underwent pulmonary resection and systematic mediastinal
lymph node dissection for lung cancer in our division. Our
incidence was much higher than the 0.5% reported by
Vallieres and associates7 or the 0.26% reported by Cerfolio
and coworkers.1 Those reports, however, described few
technical details on lymph node dissection or sampling. In
our study all patients underwent uniform, systematic medi-
astinal lymph node dissection, as described previously else-
where.2 Bollen and associates8 reported that 2 patients (3%)
who underwent systematic mediastinal lymph node dissec-
tion had chylothorax develop. Izbicki and colleagues9 re-
ported that 1 chylothorax (1.2%) occurred in their system-
TABLE 1. Patient characteristics
No. of patients
Gender
Male 21
Female 5
Postoprative N status
N0 17
N1 4
N2 5
Pathologic stage
IA 6
IB 10
IIA 0
IIB 4
IIIA 3
IIIB 3
Tumor location
Right upper lobe 11
Right middle lobe 2
Right lower lobe 5
Left upper lobe 8
Operation
Pneumonectomy 2
Bilobectomy 1
Lobectomy 23
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atic mediastinal lymph node dissection group. Their results
were comparable to ours.
The basic principle of conservative chylothorax treat-
ment is to inflate the lung to decrease the dead space in the
thoracic cavity and to promote adhesion of the lung or
pleura to the thoracic duct injury. It is important to reduce
chylous leakage to decrease the dead space and to prompt
adhesion and accelerate fistula closure. Thoracic duct flow
increases after meals, especially when a high-fat meal is
ingested.10 Because starvation reduces the thoracic duct
flow, our patients had complete oral intake cessation and
TPN after chylothorax diagnosis. Promotion of adhesion of
the lung or pleura to the thoracic duct injury by pleurodesis
may play an important role. OK-432, a heat- and penicillin-
treated lyophilized preparation of the Su strain of Strepto-
coccus pyogenes A3,11 has been reported to be effective and
safe in managing chylothorax.5 Thoracic cavity injection of
OK-432 promotes fibrin clot development, which has been
reported to facilitate pleurodesis.5 Among the 15 patients
who underwent pleurodesis with OK-432, 13 (87%) were
successfully treated without any major complications. Our
study confirmed that OK-432 is effective and safe in man-
aging postoperative chylothorax. However, we previously
reported a mediastinal chyloma after seemingly successful
conservative treatment with OK-432.6 Although that patient
might have had a chyloma develop even without OK-432
and the causal relationship between OK-432 and mediasti-
nal chyloma was unclear, it should be noted that a chyloma
may develop during the clinical course of chylothorax.
Surgical treatment generally involves ligation of the tho-
racic duct. The criteria for surgical intervention described
by Selle and coworkers12 are most frequently used in clin-
ical practice. Selle and coworkers12 recommend reoperation
to ligate the thoracic duct when chylous leakage persists for
at least 5 days at the rate of 1500 mL/day or more in adults
and when the drainage of chyle does not decrease within 2
weeks or the patient’s nutrition or metabolic status becomes
measurably more impaired during the same period. Cerfolio
and coworkers1 and Patterson and colleagues13 have re-
ported similar strategies. They recommend observation for
7 days; if drainage is still greater than 1000 mL/day, reop-
eration to ligate the thoracic duct is necessary. If drainage is
TABLE 2. Patient data
Patient
Age
(y) Operation
Diagnosis
(POD)
Chest tube
drainage
(mL)* OK432† Outcome
Reoperation
(POD)
Discharge
(POD)
1 61 Left upper lobectomy 1 150 Success 21
2 44 Right upper lobectomy 1 200 Success 24
3 47 Left pneumonectomy 3 170 Yes Success 30
4 80 Right lower lobectomy 2 300 Success 22
5 68 Right lower lobectomy 1 360 Success 21
6 53 Right lower lobectomy 2 310 Yes Success 28
7 69 Right lower lobectomy 3 180 Success 20
8 72 Right upper lobectomy 2 770 Failure 35 54
9 78 Right upper lobectomy 3 1040 Failure 17 32
10 56 Left upper lobectomy 2 230 Yes Success 43
11 65 Left pneumonectomy 1 245 Yes Failure 22 43
12 77 Right upper lobectomy 2 185 Success 14
13 70 Left upper lobectomy 2 230 Yes Success 25
14 71 Right upper lobectomy 2 90 Yes Success 23
15 57 Left upper lobectomy 2 960 Failure 5 30
16 56 Left upper lobectomy 2 47 Yes Success 21
17 69 Right upper lobectomy 2 170 Yes Success 19
18 60 Right upper lobectomy 2 100 Yes Success 19
19 61 Right middle and lower
bilobectomy
1 516 Yes Failure 14 26
20 62 Right upper lobectomy 2 120 Yes Success 21
21 54 Right upper lobectomy 1 365 Yes Success 27
22 60 Right upper lobectomy 2 420 Success 16
23 79 Right upper lobectomy 2 225 Yes Success 17
24 59 Right lower lobectomy 1 120 Success 14
25 71 Left upper lobectomy 3 335 Yes Success 16
26 61 Right middle lobectomy 1 305 Yes Success 14
POD, Postoperative day.
*Chest tube drainage during first 24 hours after complete oral intake cessation and TPN.
†Pleurodesis by intrathoracic OK432 injection.
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higher or chylothorax occurs after an esophageal operation,
early reoperation should be strongly considered. These
strategies were derived from retrospective analyses of het-
erogeneous patients who underwent general thoracic surgi-
cal procedures, including cardiovascular surgery and esoph-
ageal resection with mediastinal lymphadenectomy. Our
study, in contrast, retrospectively analyzed a homogeneous
series of consecutive patients who underwent pulmonary
resection and systematic mediastinal lymph node dissection.
This study showed that chest tube drainage less than 500
mL during the first 24 hours after complete oral intake
cessation and TPN predicted a cure with conservative treat-
ment. On the basis of our experience, we recommend the
treatment flow chart shown in Figure 2.
Chylothorax is an infrequent postoperative complication.
However, pulmonary resection for lung cancer with system-
atic mediastinal lymph node dissection may lead to a higher
incidence of postoperative chylothorax than is seen with
other general thoracic surgical procedures, except for esoph-
ageal resection with mediastinal lymphadenectomy.1 Al-
though most chylothoraces after pulmonary resection with
systematic mediastinal lymph node dissection can be cured
with a conservative strategy, immediate reoperation may be
indicated to expedite recovery and minimize hospital stay if
chest tube drainage is more than 500 mL during the first 24
hours after complete oral intake cessation and TPN.
We thank Professor J. Patrick Barron (International Medical
Communication Center, Tokyo Medical University) for reviewing
the English manuscript.
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Figure 1. Chest tube drainage during the first 24 hours after
complete oral intake cessation and TPN. Statistically significant
difference was observed between groups (P < .0001 by t test).
Figure 2. Treatment strategy for postoperative chylothorax. COIC,
Complete oral intake cessation.
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